Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

Posted on by sciencefather

Mr. Rohit Pal | Pharmaceutical Chemistry | Young Scientist Award

PhD Scholar at Acharya and BM Reddy College of Pharmacy, Bengaluru, India

Mr. Rohit Pal is a dedicated and emerging researcher in the field of pharmaceutical sciences, particularly focusing on drug discovery and development. Currently pursuing his Ph.D. at Acharya & BM Reddy College of Pharmacy in Bengaluru, he is engaged in innovative research on Pyrimidine derivatives as fourth-generation EGFR inhibitors to combat Non-Small Cell Lung Cancer (NSCLC). With a strong academic background, including an M.Pharmacy in Pharmaceutical Chemistry, Mr. Pal combines his expertise in chemical synthesis with cutting-edge computational techniques like molecular docking and structure-activity relationship (SAR) analysis. His work spans multiple research areas, including anticonvulsant activity, anti-inflammatory research, and the pharmacognostic standardization of endangered species like Passiflora vitifolia. Throughout his career, Mr. Pal has demonstrated a capacity for both in-silico drug design and experimental testing, balancing theoretical approaches with hands-on experimentation. His impressive publication record in respected journals further showcases his capability to contribute to the scientific community. As a promising young researcher, Mr. Pal’s ongoing work not only advances pharmaceutical sciences but also holds potential for meaningful clinical applications in cancer therapy and drug design.

Profile

Orcid

 

Education 🎓

Mr. Rohit Pal’s educational background demonstrates a consistent pursuit of excellence in the field of pharmaceutical sciences. He is currently enrolled in a Ph.D. program at Acharya & BM Reddy College of Pharmacy in Bengaluru, Karnataka, where his research is focused on the development of Pyrimidine derivatives as EGFR inhibitors to target Non-Small Cell Lung Cancer (NSCLC). Prior to his doctoral studies, Mr. Pal completed his M.Pharmacy in Pharmaceutical Chemistry from ISF College of Pharmacy in Moga, Punjab, achieving a notable CGPA of 9.07. His academic journey began with a B. Pharmacy from Dev Bhoomi Institute of Pharmacy and Research, Dehradun, where he gained a robust foundation in pharmaceutical sciences. Additionally, Mr. Pal holds a D. Pharmacy from SGGS College of Pharmacy, Chandigarh, further demonstrating his dedication to the field from the onset of his academic career. His varied educational experiences have shaped his interdisciplinary approach to pharmaceutical research, combining knowledge from chemistry, biology, and computational sciences. This solid academic foundation has propelled Mr. Pal to explore complex drug development challenges, particularly in cancer therapy, with a keen interest in molecular-level drug interactions.

Work Experience đź’Ľ

Mr. Rohit Pal’s professional experience reflects a promising trajectory in pharmaceutical research and drug discovery. As a Ph.D. scholar at Acharya & BM Reddy College of Pharmacy, he is deeply involved in researching Pyrimidine derivatives for EGFR inhibition in Non-Small Cell Lung Cancer (NSCLC). His research explores the design, synthesis, and evaluation of novel drug candidates, combining in-vitro testing with computational drug design. Through the use of molecular docking and structure-activity relationship (SAR) analysis, Mr. Pal aims to identify compounds with high therapeutic potential. Beyond his Ph.D. work, Mr. Pal has worked on various other research projects, including 1,2,4-triazine derivatives for anticonvulsant activity and the anti-inflammatory properties of Passiflora vitifolia, an endangered plant species. His work spans both synthetic chemistry and biological testing, allowing him to gain expertise in pharmacological assays and computational modeling. Mr. Pal’s professional experience also includes using sophisticated instruments such as HPLC, UV spectrophotometers, and Microwave Synthesizers, which complement his experimental work and ensure the reliability of his results. These experiences have positioned him well for future leadership roles in pharmaceutical research and drug developmen

Awards and Honors

Although still in the early stages of his academic career, Mr. Rohit Pal has already garnered significant recognition for his research efforts. His academic excellence is reflected in his M.Pharmacy CGPA of 9.07, placing him among the top students in his cohort. Mr. Pal’s research has been published in reputable journals such as the Journal of Biomolecular Structure and Dynamics and Chemical Physics Impact, demonstrating the impact and quality of his work. These publications are indicative of his ability to produce research that contributes to the scientific community. Despite being early in his career, his involvement in cutting-edge research on Pyrimidine derivatives and EGFR inhibitors has already gained attention within the academic and pharmaceutical fields. His dedication to molecular docking, drug design, and pharmacognostic studies positions him for further recognition. As Mr. Pal continues to contribute to innovative drug development solutions, he is likely to receive more prestigious awards and honors, reflecting the growing importance of his work in cancer research and pharmaceutical chemistry.

Research Interests

Mr. Rohit Pal’s research interests are centered around the intersection of pharmaceutical chemistry and drug discovery. His primary focus is on developing Pyrimidine derivatives as fourth-generation EGFR inhibitors aimed at Non-Small Cell Lung Cancer (NSCLC), a serious health concern with limited therapeutic options. By targeting the epidermal growth factor receptor (EGFR), his work could offer more effective treatment alternatives for cancer patients. In addition to cancer research, Mr. Pal has explored 1,2,4-triazine derivatives for evaluating anticonvulsant activity, contributing to neurological disorder treatments. He is also interested in anti-inflammatory research, with a particular focus on Passiflora vitifolia, an endangered plant species, aiming to standardize its pharmacognostic properties. His multidisciplinary approach extends to the application of computational drug design, where he utilizes molecular docking and molecular dynamics simulations to predict drug-receptor interactions. Mr. Pal is committed to advancing drug development by combining experimental chemistry with in-silico methodologies, offering innovative solutions for complex healthcare challenges. His work on drug repurposing, targeted therapies, and sustainable drug sourcing reflects his holistic approach to addressing both scientific and global health concerns.

Research Skills

Mr. Rohit Pal possesses a wide range of research skills essential for successful pharmaceutical research. His proficiency in chemical synthesis includes techniques such as recrystallization, sublimation, and flash chromatography, which he applies to purify and isolate new compounds for testing. In addition to these laboratory techniques, Mr. Pal is highly skilled in analytical methods, including HPLC and UV spectrophotometry, to assess the purity and chemical composition of compounds. He is also adept at utilizing computational tools for drug design, particularly AutoDock, Biovia Drug Discovery Studio, and Pymol, to perform molecular docking and molecular dynamics simulations. These tools allow him to predict the interactions between drug candidates and their targets, enhancing the efficiency of drug development. Furthermore, Mr. Pal has experience in in-vitro biological testing, including assays for anticonvulsant, anti-inflammatory, and antioxidant activities, ensuring the biological relevance of his synthesized compounds. His ability to combine experimental techniques with computational modeling equips him to approach drug discovery from both theoretical and practical angles, ensuring well-rounded and impactful research outcomes.

đź“š Publications

  • Design, synthesis, and biological evaluation of novel 4-(4-ethoxyphenyl)-6-(substituted-phenyl)pyrimidin-2-amine/thiol/hydroxy derivatives as EGFRWT and EGFRT790M inhibitors targeting NSCLC: In-vitro and in-silico exploration
    • Journal: Journal of Molecular Structure
    • DOI: 10.1016/j.molstruc.2024.141227
    • Date: April 2025
    • Contributors: Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Ghanshyam Teli; Viney Chawla; Pooja A. Chawla
  • Next-generation cancer therapeutics: PROTACs and the role of heterocyclic warheads in targeting resistance
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.117034
    • Date: January 2025
    • Contributors: Ebna Azizal Omar; Rajesh R.; Pronoy Kanti Das; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Lalmohan Maji
  • Benzothiazole a privileged scaffold for cutting-edge anticancer agents: Exploring drug design, structure-activity relationship, and docking studies
    • Journal: European Journal of Medicinal Chemistry
    • DOI: 10.1016/j.ejmech.2024.116831
    • Date: December 2024
    • Contributors: Aayishamma I; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Abhishek Ghara; Nimmagadda Venkata Satya Sai Aishwarya; Kumaraswamy B; Ketan R. Hosamani; Manjushree B V; Haripriya E
  • An outlook of docking analysis and structure-activity relationship of pyrimidine-based analogues as EGFR inhibitors against non-small cell lung cancer (NSCLC)
    • Journal: Journal of Biomolecular Structure and Dynamics
    • DOI: 10.1080/07391102.2023.2252082
    • Date: December 11, 2024
    • Contributors: Rohit Pal; Ghanshyam Teli; Sindhuja Sengupta; Lalmohan Maji; Gurubasavaraja Swamy Purawarga Matada
  • Exploring the anticancer potential of triazine derivatives: An outlook of designing strategies, docking studies, and structure-activity relationships (SAR)
    • Journal: ChemistrySelect
    • DOI: 10.1002/slct.202402766
    • Date: November 2024
    • Contributors: B. V. Manjushree; Gurubasavaraja Swamy Purawarga Matada; Rohit Pal; Md. Ashadul Sk; M. P. Viji; Nimmagadda Venkata Satya Sai Aishwarya; Pronoy Kanti Das; I. Aayishamma; S. Mounika
  • Pyrazole, pyrazoline, and fused pyrazole derivatives: New horizons in EGFR-targeted anticancer agents
    • Journal: Chemistry & Biodiversity
    • DOI: 10.1002/cbdv.202400880
    • Date: November 2024
    • Contributors: Ketan R Hosamani; Hemalatha K; Rohit Pal; Gurubasavaraja Swamy Purawarga Matada; Kumaraswamy B; Aayishamma I; Nimmagadda Venkata Satya Sai Aishwarya

Conclusion 

Mr. Rohit Pal is an exceptionally talented and promising researcher in the field of pharmaceutical sciences. His research, focused on Pyrimidine derivatives as EGFR inhibitors for Non-Small Cell Lung Cancer (NSCLC), is not only innovative but holds significant promise for advancing cancer treatment. His combination of chemical synthesis, computational drug design, and biological testing reflects his multidisciplinary approach to pharmaceutical research. Mr. Pal’s commitment to anti-inflammatory, anticonvulsant, and pharmacognostic standardization further demonstrates his versatility as a researcher. While still in the early stages of his career, his publication record and expertise in molecular docking and drug design suggest that he is well on his way to becoming a leader in pharmaceutical research. His ongoing work could contribute to groundbreaking advancements in cancer therapy, neurological disorder treatments, and sustainable drug sourcing. With his strong educational background, solid professional experience, and growing body of work, Mr. Rohit Pal is undoubtedly a candidate with the potential to make meaningful contributions to drug development and global health. His future in research looks bright, and he is well-positioned for recognition in upcoming awards such as the Young Scientist Award.